首頁 > 市場調查報告書 > 製藥

精神疾病

市場調查報告書

商品編碼

2103121

全球失眠流行病學分析與預測：2026 年

Global Insomnia Epidemiology Analysis and Forecast, 2026

出版日期: 2026年07月11日 | 出版商:

Knowledge Sourcing Intelligence | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

據估計，全球失眠症患者人數將從 2026 年的 6,640 萬增加到 2035 年的 7,110 萬，年複合成長率為 0.8%。

全球失眠流行病學格局反映了日益嚴重的公共衛生負擔，失眠已被公認為全球最常見的睡眠障礙之一。流行病學分析能夠全面揭示失眠的盛行率、發生率、確診患者人數、人口趨勢、疾病嚴重程度、風險因素、地理分佈以及未來流行病學預測。睡眠健康意識的提高、人口老化、壓力水平上升、心理健康問題以及生活方式的改變，都持續加劇著已開發經濟體和新興經濟體中失眠的疾病負擔。

失眠的特徵是持續難以入睡、難以維持睡眠或難以獲得充分的睡眠，即使有充足的休息機會，也會導致白天功能受損。近期全球流行病學數據顯示，全球約有8.52億成年人患有臨床意義上的失眠症，約佔全球成年人口的16.2%。此外，約有4.15億成年人患有重度失眠。在所有年齡層中，女性的盛行率始終高於男性，且疾病負擔老齡化增加而加重。

失眠的流行病學受多種生物學、心理學、環境和社會經濟因素的影響。焦慮症、憂鬱症、心血管疾病、慢性疼痛、神經系統疾病、肥胖、輪班工作、過度使用電子螢幕以及老化都會導致失眠盛行率上升。此外，都市化、工作方式的改變以及電子設備使用量的增加正在加劇許多人群的睡眠障礙，帶來新的醫學挑戰。

數位健康技術、睡眠監測設備、穿戴式感測器、人工智慧診斷和遠端醫療的進步正在改善疾病檢測和患者監測。此外，人們越來越認知到失眠是一種獨立的疾病，而不僅僅是其他疾病的症狀，這促使診斷率提高，臨床干預也更加及時。隨著醫療保健系統繼續重視睡眠醫學和預防保健，預計在預測期內，確診患者人數將穩定成長。

市場促進因素

全球睡眠障礙負擔日益加重

在全球範圍內，由於壓力增加、精神疾病、老化和生活方式改變等因素，失眠症的盛行率持續上升。

大眾對睡眠健康的認知不斷提高，正在加速早期診斷和治療。

人們對心理健康的認知不斷提高

憂鬱症、焦慮症和慢性心理壓力仍然是失眠的主要因素。

精神健康服務的擴展使得睡眠障礙能夠更早被發現和妥善治療。

人口老化

由於與老齡化相關的生理變化、慢性疾病和多種合併症，老年人失眠的發生率較高。

由於全球人口老化，預計在預測期內患者總數將會增加。

睡眠醫療服務的擴展

在醫療保健系統中，對睡眠診所、專業診斷中心、遠端醫療平台和多學科睡眠管理計畫的投資仍在繼續。

專家會診管道的改善提高了診斷率。

診斷技術的進步

穿戴式睡眠監測器、數位睡眠日記、居家睡眠評估工具、人工智慧和遠端患者監護技術正在改善疾病識別和長期流行病學追蹤。

區域分析

北美地區失眠症確診患者數量位居世界前列，這得益於該地區對失眠症的高度認知、先進的醫療基礎設施、睡眠醫學專家的廣泛普及以及數位醫療技術的廣泛應用。較高的社會認知度和常規臨床篩檢持續支撐著較高的診斷率。

在歐洲，儘管擁有完善的醫療保健體系、專業的睡眠醫學中心以及對預防醫學日益成長的投入，仍有相當數量的人飽受失眠之苦。德國、英國、法國、義大利和西班牙報告稱，儘管行為睡眠療法和數位醫療服務的普及程度有所提高，但失眠症的負擔依然沉重。

在亞太地區，快速的都市化、日益成長的職業壓力、人口老化、不斷擴大的醫療保健基礎設施以及人們意識的提高，預計將推動中國、日本、印度、韓國和澳洲在預測期內失眠診斷數量成長最快。

在拉丁美洲、中東和非洲，隨著醫療保健的現代化、睡眠醫學服務的擴展、意識提升以及精神健康保健服務的改善，失眠的診斷正在逐步改善。

本報告調查了全球失眠市場，並重點關注流行病學趨勢。報告概述了失眠症及其臨床背景，分析了受影響患者人數、新患者、確診患者和接受治療患者人數的趨勢和預測，並按年齡層、性別和嚴重程度等不同類別進行了詳細分析，還分析了各地區和主要國家的趨勢、相關政策法規、競爭格局、主要公司概況以及未來前景。

評估已確診患者人數
- 全球確診患者人數
- 區域診斷率
- 過去的診斷趨勢
對診斷過程的評估
- 患者就診時的症狀和病情
- 基層醫療中的診斷
- 專科醫生的診斷
- 延遲診斷
評估未確診的患者數量
- 未確診患者人數估計
- 診斷障礙
- 缺乏意識

第6章：接受治療患者人數分析

尋求治療的患者群體
- 醫療利用率
- 就醫趨勢
- 治療啟動率
評估接受治療的患者人數
- 接受藥物治療的患者人數
- 接受非藥物治療的患者人數
- 接受聯合治療的患者人數
評估未治療患者的數量
- 治療缺口
- 獲得治療的障礙
- 經濟制約

第7章人口統計學和臨床分期

基於年齡的分析
- 兒童
- 青年
- 成人
- 老年人
性別分析
- 女士
- 男性患者
- 性相關疾病的趨勢
按嚴重程度分析
- 溫和的
- 緩和
- 嚴重
按合併症進行分析
- 精神疾病的共病
- 心血管併發症
- 神經系統併發症
- 代謝併發症

第8章流行病學預測分析

世界預測
- 患病率預測
- 發病率預測
- 預計確診患者人數
- 預測需要治療的患者人數
預測因素
- 人口老化
- 都市化趨勢
- 精神健康障礙的負擔
- 生活方式的改變
預測的限制
- 未確診
- 醫療保健服務獲取限制
- 缺乏意識

第9章：醫療保健服務取得與病人就醫歷程分析

患者就診過程評估
- 症狀識別
- 參觀醫療機構
- 診斷
- 開始治療
醫療保健服務獲取分析
- 獲得基層醫療
- 睡眠專家的可近性
- 數位健康應用
治療機會評估
- 地理位置上的差異
- 社會經濟地位差異所導致的獲取機會不平等
- 對保險範圍的影響

第10章區域分析

北美洲
歐洲
亞太地區
拉丁美洲

第11章主要國家分析

加拿大
德國
中國
日本
印度

第12章：公共衛生與經濟負擔分析

醫療資源的利用
- 門診就診
- 使用睡眠診所
- 對醫院醫療資源的影響
經濟負擔評估
- 直接醫療費用
- 生產力損失造成的間接成本
- 雇主的負擔
公共衛生舉措
- 意識提升計劃
- 睡眠健康宣傳活動
- 改善醫療保健服務取得途徑的努力

第13章：未來展望與策略洞察

流行病學視角
- 疾病流行率的長期趨勢
- 發病率的長期趨勢
- 診斷率趨勢
醫療保健系統展望
- 睡眠醫療服務的擴展
- 遠端醫療的引入
- 數位睡眠健康監測
戰略洞察
- 疾病負擔較重的患者族群
- 醫療服務不足的地區
- 優先醫療干預

第14章：調查方法與資料框架

簡介目錄

Product Code: KSI-008923

The Global Insomnia prevelance is estimated to grow from USD 66.4 million patients in 2026 at a CAGR of 0.8% to USD 71.1 million patients in 2035.

The global insomnia epidemiology landscape reflects a significant and growing public health burden, with insomnia recognized as one of the most prevalent sleep disorders worldwide. Epidemiology analysis provides comprehensive insights into disease prevalence, incidence, diagnosed patient populations, demographic trends, disease severity, risk factors, regional distribution, and future epidemiological projections. Increasing awareness of sleep health, aging populations, rising stress levels, mental health disorders, and changing lifestyles continue to contribute to the growing burden of insomnia across both developed and emerging economies.

Insomnia is characterized by persistent difficulty initiating sleep, maintaining sleep, or experiencing restorative sleep despite adequate opportunity for rest, leading to impaired daytime functioning. Recent global epidemiological evidence estimates that approximately 852 million adults worldwide are living with clinically significant insomnia, representing approximately 16.2% of the global adult population, while nearly 415 million adults experience severe insomnia. Women consistently demonstrate higher prevalence rates than men across all age groups, and disease burden increases with advancing age.

The epidemiology of insomnia is influenced by numerous biological, psychological, environmental, and socioeconomic factors. Anxiety disorders, depression, cardiovascular disease, chronic pain, neurological disorders, obesity, shift work, excessive screen exposure, and aging all contribute to increased disease prevalence. Urbanization, changing work patterns, and increasing digital device usage have further intensified sleep disturbances in many populations, creating additional healthcare challenges.

Advances in digital health technologies, sleep monitoring devices, wearable sensors, artificial intelligence-assisted diagnostics, and telemedicine are improving disease detection and patient monitoring. Greater recognition of insomnia as an independent medical condition rather than merely a symptom of other illnesses has also improved diagnosis rates and encouraged earlier clinical intervention. As healthcare systems continue prioritizing sleep medicine and preventive healthcare, the diagnosed patient population is expected to expand steadily throughout the forecast period.

Market Drivers

Rising Global Burden of Sleep Disorders

Increasing stress, mental health disorders, aging populations, and lifestyle changes continue contributing to higher insomnia prevalence worldwide.

Growing public awareness of sleep health is encouraging earlier diagnosis and treatment.

Increasing Mental Health Awareness

Depression, anxiety disorders, and chronic psychological stress remain among the strongest contributors to insomnia.

Expanding mental health services are improving identification and management of sleep disorders.

Aging Population

Older adults experience higher rates of insomnia due to age-related physiological changes, chronic illnesses, and multiple comorbidities.

Global population aging is expected to increase the overall patient population during the forecast period.

Expansion of Sleep Medicine Services

Healthcare systems continue investing in sleep clinics, specialized diagnostic centers, telemedicine platforms, and multidisciplinary sleep management programs.

Improved access to specialist care is strengthening diagnosis rates.

Advances in Diagnostic Technologies

Wearable sleep monitors, digital sleep diaries, home sleep assessment tools, artificial intelligence, and remote patient monitoring technologies are improving disease identification and long-term epidemiological tracking.

Market Restraints

Underdiagnosis

A significant proportion of individuals with chronic insomnia remain undiagnosed because symptoms are frequently underestimated or self-managed without professional medical evaluation.

Limited awareness continues delaying appropriate treatment.

Limited Access to Sleep Specialists

Many developing countries continue facing shortages of sleep medicine specialists, diagnostic laboratories, and dedicated sleep centers.

Healthcare disparities restrict timely diagnosis and treatment.

Variability in Diagnostic Criteria

Differences in clinical definitions, diagnostic methodologies, and epidemiological study designs may create variability in prevalence estimates across countries and regions.

Standardization remains an ongoing challenge for epidemiological research.

Epidemiology Insights

By Disease Severity

The patient population includes individuals with transient insomnia, short-term insomnia, chronic insomnia disorder, and severe insomnia requiring long-term medical management.

Chronic insomnia represents the greatest clinical and economic burden because of its association with multiple comorbid conditions.

By Age Group

Insomnia affects adults of all ages but is most frequently diagnosed among middle-aged and older adults.

Prevalence generally increases with age because of physiological sleep changes, chronic diseases, medication use, and psychiatric comorbidities.

By Gender

Women experience insomnia more frequently than men due to hormonal changes, pregnancy, menopause, and a higher prevalence of anxiety and depression.

Recent epidemiological studies consistently report higher insomnia prevalence among females across virtually all adult age groups.

By Diagnosis Status

The epidemiological population includes diagnosed patients receiving pharmacological or behavioral treatment, newly diagnosed individuals, and a substantial proportion of undiagnosed or untreated patients who continue experiencing chronic sleep disturbances.

Regional Insights

North America represents one of the largest diagnosed insomnia populations owing to high disease awareness, advanced healthcare infrastructure, widespread access to sleep medicine specialists, and extensive use of digital health technologies. Strong public awareness and routine clinical screening continue supporting higher diagnosis rates.

Europe maintains a significant insomnia patient population supported by comprehensive healthcare systems, specialized sleep medicine centers, and increasing investment in preventive healthcare. Germany, the United Kingdom, France, Italy, and Spain continue reporting substantial disease burden while expanding access to behavioral sleep therapies and digital health services.

Asia Pacific is expected to witness the fastest growth in diagnosed insomnia cases during the forecast period due to rapid urbanization, increasing occupational stress, aging populations, expanding healthcare infrastructure, and improving awareness across China, Japan, India, South Korea, and Australia.

Latin America and the Middle East & Africa are gradually improving insomnia diagnosis through healthcare modernization, expanded sleep medicine services, increased public awareness, and improved access to mental health care.

Competitive and Strategic Outlook

The growing epidemiological burden of insomnia continues creating significant opportunities for pharmaceutical companies, healthcare providers, sleep diagnostic companies, digital health developers, and medical device manufacturers. Organizations are increasingly investing in improved screening programs, digital diagnostics, wearable sleep technologies, remote patient monitoring, and personalized sleep medicine to better identify and manage affected individuals.

Strategic collaboration between healthcare providers, academic institutions, sleep research organizations, pharmaceutical companies, and digital health developers continues strengthening epidemiological surveillance while supporting improved patient outcomes. Future healthcare strategies are expected to emphasize early diagnosis, preventive care, precision medicine, and integration of digital sleep technologies into routine clinical practice.

Conclusion

The global epidemiological burden of insomnia is expected to increase steadily throughout the forecast period as aging populations, mental health disorders, changing lifestyles, and chronic disease prevalence continue expanding the at-risk population. Recent evidence indicates that more than 852 million adults worldwide are affected by clinically significant insomnia, highlighting its substantial impact on public health. Continued improvements in disease awareness, diagnostic technologies, healthcare accessibility, and sleep medicine services are expected to enhance diagnosis rates and support more effective long-term disease management. Despite ongoing challenges related to underdiagnosis, healthcare disparities, and variability in diagnostic practices, continued investment in sleep health and epidemiological research is expected to strengthen patient care and healthcare planning worldwide.

Key Benefits of this Report

Insightful Analysis: Comprehensive evaluation of global insomnia prevalence, incidence, diagnosed patient population, demographic trends, and disease burden.
Epidemiological Assessment: Analyze patient distribution by age, gender, disease severity, diagnosis status, and geographic region.
Market Drivers and Future Trends: Understand epidemiological developments, healthcare access improvements, and future patient population growth.
Actionable Recommendations: Support healthcare planning, market forecasting, clinical development, and commercial strategy.
Caters to a Wide Audience: Suitable for pharmaceutical companies, biotechnology firms, healthcare providers, investors, consultants, research organizations, public health agencies, and policymakers.

What Businesses Use Our Reports For

Epidemiology assessment, patient population forecasting, commercial opportunity evaluation, clinical trial planning, healthcare resource allocation, market entry strategy, investment analysis, public health planning, and competitive intelligence.

Report Coverage

Historical analysis from 2021 to 2024, Base year 2025, and Forecast period from 2026 to 2035
Epidemiological analysis by prevalence, incidence, diagnosed cases, disease severity, age group, gender, and region
Assessment of risk factors, disease burden, diagnosis patterns, healthcare access, and future epidemiological trends
Analysis of unmet clinical needs, healthcare infrastructure, and patient management trends
Regional analysis across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

1. Executive Summary

1.1 Report Overview
- 1.1.1 Study Objectives
- 1.1.2 Scope of Analysis
- 1.1.3 Key Epidemiological Findings
1.2 Epidemiology Snapshot
- 1.2.1 Global Prevalence Overview
- 1.2.2 Global Incidence Overview
- 1.2.3 Diagnosed Population Overview
- 1.2.4 Treated Population Overview
1.3 Forecast Highlights (2025-2045)
- 1.3.1 Patient Population Growth Trends
- 1.3.2 Diagnosis Trends
- 1.3.3 Treatment Access Trends

2. Disease Overview and Clinical Background

2.1 Insomnia Overview
- 2.1.1 Definition and Classification
- 2.1.2 Acute Insomnia
- 2.1.3 Chronic Insomnia
- 2.1.4 Comorbid Insomnia
2.2 Disease Pathophysiology
- 2.2.1 Neurobiological Mechanisms
- 2.2.2 Sleep-Wake Regulation Dysfunction
- 2.2.3 Risk Factors
2.3 Disease Burden Assessment
- 2.3.1 Individual Health Burden
- 2.3.2 Mental Health Impact
- 2.3.3 Productivity Loss
- 2.3.4 Healthcare Resource Utilization

3. Epidemiology Methodology and Data Framework

3.1 Data Collection Methodology
- 3.1.1 Population-Based Studies
- 3.1.2 Government Health Databases
- 3.1.3 Academic Literature Sources
- 3.1.4 Registry and Survey Data
3.2 Epidemiological Definitions
- 3.2.1 Total Population
- 3.2.2 Prevalent Cases
- 3.2.3 Incident Cases
- 3.2.4 Diagnosed Cases
- 3.2.5 Treated Cases
3.3 Forecast Methodology
- 3.3.1 Baseline Population Modeling
- 3.3.2 Forecast Assumptions
- 3.3.3 Sensitivity Analysis

4. Global Insomnia Epidemiology Analysis

4.1 Total Patient Population
- 4.1.1 Historical Trends
- 4.1.2 Current Epidemiological Burden
- 4.1.3 Future Population Trends
4.2 Prevalence Analysis
- 4.2.1 Global Prevalence
- 4.2.2 Age-Specific Prevalence
- 4.2.3 Gender-Specific Prevalence
- 4.2.4 Regional Variability
4.3 Incidence Analysis
- 4.3.1 Global Incidence
- 4.3.2 Annual New Cases
- 4.3.3 Age-Specific Incidence
- 4.3.4 Gender-Specific Incidence

5. Diagnosed Patient Population Analysis

5.1 Diagnosed Cases Assessment
- 5.1.1 Global Diagnosed Population
- 5.1.2 Regional Diagnosis Rates
- 5.1.3 Historical Diagnosis Trends
5.2 Diagnostic Pathway Evaluation
- 5.2.1 Patient Presentation Patterns
- 5.2.2 Primary Care Diagnosis
- 5.2.3 Specialist Diagnosis
- 5.2.4 Diagnostic Delays
5.3 Undiagnosed Population Assessment
- 5.3.1 Estimated Undiagnosed Population
- 5.3.2 Barriers to Diagnosis
- 5.3.3 Awareness Gaps

6. Treated Patient Population Analysis

6.1 Treatment-Seeking Population
- 6.1.1 Healthcare Utilization Rates
- 6.1.2 Physician Consultation Trends
- 6.1.3 Treatment Initiation Rates
6.2 Treated Population Assessment
- 6.2.1 Pharmacological Treatment Population
- 6.2.2 Non-Pharmacological Treatment Population
- 6.2.3 Combined Treatment Population
6.3 Untreated Population Assessment
- 6.3.1 Treatment Gaps
- 6.3.2 Access Barriers
- 6.3.3 Economic Constraints

7. Demographic and Clinical Segmentation

7.1 Age-Based Analysis
- 7.1.1 Pediatric Population
- 7.1.2 Adolescent Population
- 7.1.3 Adult Population
- 7.1.4 Elderly Population
7.2 Gender-Based Analysis
- 7.2.1 Female Patient Population
- 7.2.2 Male Patient Population
- 7.2.3 Gender-Related Disease Trends
7.3 Severity-Based Analysis
- 7.3.1 Mild Insomnia
- 7.3.2 Moderate Insomnia
- 7.3.3 Severe Insomnia
7.4 Comorbidity-Based Analysis
- 7.4.1 Psychiatric Comorbidities
- 7.4.2 Cardiovascular Comorbidities
- 7.4.3 Neurological Comorbidities
- 7.4.4 Metabolic Comorbidities

8. Epidemiological Forecast Analysis (2025-2045)

8.1 Global Forecast
- 8.1.1 Prevalence Forecast
- 8.1.2 Incidence Forecast
- 8.1.3 Diagnosed Population Forecast
- 8.1.4 Treated Population Forecast
8.2 Forecast Drivers
- 8.2.1 Population Aging
- 8.2.2 Urbanization Trends
- 8.2.3 Mental Health Burden
- 8.2.4 Lifestyle Changes
8.3 Forecast Constraints
- 8.3.1 Underdiagnosis
- 8.3.2 Healthcare Access Limitations
- 8.3.3 Awareness Deficits

9. Healthcare Access and Patient Journey Analysis

9.1 Patient Journey Assessment
- 9.1.1 Symptom Recognition
- 9.1.2 Healthcare Engagement
- 9.1.3 Diagnosis
- 9.1.4 Treatment Initiation
9.2 Healthcare Access Analysis
- 9.2.1 Primary Care Access
- 9.2.2 Sleep Specialist Availability
- 9.2.3 Digital Health Utilization
9.3 Treatment Access Assessment
- 9.3.1 Geographic Access Differences
- 9.3.2 Socioeconomic Access Differences
- 9.3.3 Insurance Coverage Impact

10. Geographic Analysis

10.1 North America
- 10.1.1 Prevalence Trends
- 10.1.2 Incidence Trends
- 10.1.3 Diagnosis Trends
- 10.1.4 Treatment Access
10.2 Europe
- 10.2.1 Prevalence Trends
- 10.2.2 Incidence Trends
- 10.2.3 Diagnosis Trends
- 10.2.4 Treatment Access
10.3 Asia-Pacific
- 10.3.1 Prevalence Trends
- 10.3.2 Incidence Trends
- 10.3.3 Diagnosis Trends
- 10.3.4 Treatment Access
10.4 Latin America
- 10.4.1 Prevalence Trends
- 10.4.2 Incidence Trends
- 10.4.3 Diagnosis Trends
- 10.4.4 Treatment Access
10.5 Middle East & Africa
- 10.5.1 Prevalence Trends
- 10.5.2 Incidence Trends
- 10.5.3 Diagnosis Trends
- 10.5.4 Treatment Access

11. Key Countries Analysis

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 China
11.9 Japan
11.10 India
11.11 South Korea
11.12 Australia
11.13 Brazil
11.14 Mexico
11.15 Saudi Arabia
11.16 South Africa

12. Public Health and Economic Burden Analysis

12.1 Healthcare Resource Utilization
- 12.1.1 Outpatient Visits
- 12.1.2 Sleep Clinic Utilization
- 12.1.3 Hospital Resource Impact
12.2 Economic Burden Assessment
- 12.2.1 Direct Medical Costs
- 12.2.2 Indirect Productivity Costs
- 12.2.3 Employer Burden
12.3 Public Health Initiatives
- 12.3.1 Awareness Programs
- 12.3.2 Sleep Health Campaigns
- 12.3.3 Access Improvement Initiatives

13. Future Outlook and Strategic Insights

13.1 Epidemiological Outlook
- 13.1.1 Long-Term Prevalence Trends
- 13.1.2 Long-Term Incidence Trends
- 13.1.3 Diagnosis Rate Evolution
13.2 Healthcare System Outlook
- 13.2.1 Expansion of Sleep Medicine Services
- 13.2.2 Telehealth Adoption
- 13.2.3 Digital Sleep Health Monitoring
13.3 Strategic Insights
- 13.3.1 High-Burden Populations
- 13.3.2 Underserved Regions
- 13.3.3 Priority Healthcare Interventions

14. Methodology and Data Framework

14.1 Data Sources
- 14.1.1 Government Agencies
- 14.1.2 Academic Publications
- 14.1.3 International Health Organizations
- 14.1.4 National Health Surveys
14.2 Forecasting Methodology
- 14.2.1 Population Modeling
- 14.2.2 Epidemiological Modeling
- 14.2.3 Validation Procedures
14.3 Quality Assurance
- 14.3.1 Data Verification
- 14.3.2 Cross-Source Validation
- 14.3.3 Limitations Assessment